B L Adler1, M K Pezhouh2, A Kim3, L Luan2, Q Zhu2, F Gani4, M Yarchoan5, J Chen6, L Voltaggio2, A Parian3, M Lazarev3, G Y Lauwers6, T M Pawlik7, E A Montgomery2, E Jaffee5,8, D T Le5, J M Taube2,8, R A Anders2,8. 1. Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. Department of Pathology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA. 7. Department of Surgery, Ohio State University Wexner Medical Center, Columbus, OH, USA. 8. The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
Abstract
BACKGROUND: Use of the immune checkpoint inhibitor ipilimumab is sometimes complicated by ipilimumab-associated colitis (Ipi-AC), an immune-mediated colitis that mimics inflammatory bowel disease. OBJECTIVE: We sought to characterize the histopathologic and immunophenotypic features of Ipi-AC and to directly compare these features to ulcerative colitis (UC). METHODS: This is a retrospective cohort study of 22 patients with Ipi-AC, 12 patients with treatment-naïve UC and five controls with diarrhoea but normal endoscopic findings. Immunohistopathologic features were described, and quantitative immunohistochemistry (IHC) was performed for CD4, CD8, CD20, CD138 and FOXP3. RESULTS: Endoscopic findings in both the Ipi-AC and UC groups included ulcerated, oedematous and erythematous mucosa. Involvement of the GI tract was more diffuse in Ipi-AC. As compared to UC, a smaller proportion of Ipi-AC biopsies had basal plasmacytosis (14% for Ipi-AC vs. 92% for UC, P < 0.0001) and crypt distortion (23% for Ipi-AC vs. 75% for UC, P = 0.003), whereas Ipi-AC biopsies had more apoptotic bodies in the left colon (17.6 ± 15.3 for Ipi-AC vs. 8.2 ± 4.2 for UC, P = 0.011). Cryptitis, ulcerations and crypt abscesses were common in both groups. Biopsy specimens from Ipi-AC had a lower density of CD20-positive lymphocytes than UC (275.8 ± 253.3 cells mm-2 for Ipi-AC vs. 1173.3 ± 1158.2 cells mm-2 for UC, P = 0.022) but had a similar density of CD4, CD8, CD138 and FOXP3-positive cells. CONCLUSIONS: Ipi-AC is a distinct pathologic entity with notable clinical and histopathological differences compared to UC. These findings provide insights into the pathophysiology of immune-related adverse events (iAEs) from ipilimumab therapy.
BACKGROUND: Use of the immune checkpoint inhibitor ipilimumab is sometimes complicated by ipilimumab-associated colitis (Ipi-AC), an immune-mediated colitis that mimics inflammatory bowel disease. OBJECTIVE: We sought to characterize the histopathologic and immunophenotypic features of Ipi-AC and to directly compare these features to ulcerative colitis (UC). METHODS: This is a retrospective cohort study of 22 patients with Ipi-AC, 12 patients with treatment-naïve UC and five controls with diarrhoea but normal endoscopic findings. Immunohistopathologic features were described, and quantitative immunohistochemistry (IHC) was performed for CD4, CD8, CD20, CD138 and FOXP3. RESULTS: Endoscopic findings in both the Ipi-AC and UC groups included ulcerated, oedematous and erythematous mucosa. Involvement of the GI tract was more diffuse in Ipi-AC. As compared to UC, a smaller proportion of Ipi-AC biopsies had basal plasmacytosis (14% for Ipi-AC vs. 92% for UC, P < 0.0001) and crypt distortion (23% for Ipi-AC vs. 75% for UC, P = 0.003), whereas Ipi-AC biopsies had more apoptotic bodies in the left colon (17.6 ± 15.3 for Ipi-AC vs. 8.2 ± 4.2 for UC, P = 0.011). Cryptitis, ulcerations and crypt abscesses were common in both groups. Biopsy specimens from Ipi-AC had a lower density of CD20-positive lymphocytes than UC (275.8 ± 253.3 cells mm-2 for Ipi-AC vs. 1173.3 ± 1158.2 cells mm-2 for UC, P = 0.022) but had a similar density of CD4, CD8, CD138 and FOXP3-positive cells. CONCLUSIONS:Ipi-AC is a distinct pathologic entity with notable clinical and histopathological differences compared to UC. These findings provide insights into the pathophysiology of immune-related adverse events (iAEs) from ipilimumab therapy.
Authors: David Berman; Susan M Parker; Jonathan Siegel; Scott D Chasalow; Jeffrey Weber; Susan Galbraith; Stephan R Targan; Hanlin L Wang Journal: Cancer Immun Date: 2010-11-24
Authors: Ajay V Maker; Giao Q Phan; Peter Attia; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Leah R Haworth; Catherine Levy; David Kleiner; Sharon A Mavroukakis; Michael Yellin; Steven A Rosenberg Journal: Ann Surg Oncol Date: 2005-10-21 Impact factor: 5.344
Authors: William J Sandborn; Jean-Frederic Colombel; Bruce E Sands; Paul Rutgeerts; Stephan R Targan; Remo Panaccione; Brian Bressler; Karl Geboes; Stefan Schreiber; Richard Aranda; Sheila Gujrathi; Allison Luo; Yun Peng; Luisa Salter-Cid; Stephen B Hanauer Journal: Gastroenterology Date: 2012-04-12 Impact factor: 22.682
Authors: Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang Journal: J Clin Oncol Date: 2006-05-20 Impact factor: 44.544
Authors: Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman Journal: Cancer Immunol Res Date: 2013-04-07 Impact factor: 11.151
Authors: Eduard Cornelis Verschuren; Alfonsus Johannes van den Eertwegh; Janneke Wonders; Rob Michel Slangen; Foke van Delft; Adriaan van Bodegraven; Andra Neefjes-Borst; Nanne Klaas de Boer Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382
Authors: Mohammad Jafarnejad; Chang Gong; Edward Gabrielson; Imke H Bartelink; Paolo Vicini; Bing Wang; Rajesh Narwal; Lorin Roskos; Aleksander S Popel Journal: AAPS J Date: 2019-06-24 Impact factor: 4.009